has in a $27.8bn (拢22.76bn) deal following US Federal Trade Commission (FTC) approval.
The latest acquisition will bolster the inflammation portfolio of Amgen by adding Horizon鈥檚 medicines for treating rare inflammatory ailments.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Thank you!
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form
By GlobalDataThese medicines include Tepezza (teprotumumab-trbw), Krystexxa (pegloticase) and Uplizna (inebilizumab-cdon).
In December 2022, Amgen entered an agreement to acquire the complete ordinary share capital of Horizon.
In May 2023, the FTC sued Amgen, blocking the Horizon takeover and claiming that the deal would 鈥渆ntrench monopoly drugs鈥� intended for treating serious ailments.
In September 2023, Amgen and Horizon entered a consent order agreement with the FTC to resolve the lawsuit.
Amgen is barred from bundling its product with either Tepezza or Krystexxa.
Tepezza treats thyroid eye disease and Krystexxa is a chronic refractory gout treatment.
Amgen chairman and CEO Robert Bradway stated: 鈥淭oday marks an exciting milestone as we welcome Horizon employees to Amgen and begin working together to serve even more patients around the world suffering from serious illnesses.
鈥淲e have strong momentum in our core business and the addition of Horizon will further position Amgen as a leader across a broader range of diseases.鈥�
